Kiniksa Pharmaceuticals (KNSA) News Today $21.21 +0.39 (+1.87%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?November 13, 2024 | msn.comKiniksa Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNovember 12, 2024 | globenewswire.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $40.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. lifted their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a report on Tuesday.November 5, 2024 | marketbeat.comHarbor Capital Advisors Inc. Acquires New Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Harbor Capital Advisors Inc. purchased a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 97,543 shares of the company's stock, valued at approximNovember 5, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Consensus Rating of "Buy" by BrokeragesShares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) have been given an average rating of "Buy" by the five analysts that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price tNovember 2, 2024 | marketbeat.comKiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest ForecastsNovember 1, 2024 | finance.yahoo.comRice Hall James & Associates LLC Increases Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Rice Hall James & Associates LLC raised its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 8.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 649,630 shares of the company's stock aftNovember 1, 2024 | marketbeat.comKiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | seekingalpha.comBullish Outlook on Kiniksa Pharmaceuticals Driven by Arcalyst’s Billion-Dollar Potential and Strategic Growth InitiativesNovember 1, 2024 | markets.businessinsider.comKiniksa Pharmaceuticals Faces Financial Risks from Global Currency FluctuationsNovember 1, 2024 | markets.businessinsider.comWedbush Has Pessimistic Outlook of KNSA FY2024 EarningsKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Analysts at Wedbush decreased their FY2024 earnings per share estimates for Kiniksa Pharmaceuticals in a research report issued on Tuesday, October 29th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.42) perOctober 31, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $35.00Evercore ISI increased their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Wednesday.October 30, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Posts Quarterly Earnings ResultsKiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The business had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. Kiniksa Pharmaceuticals's revenue for the quarter was up 67.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.20) EPS.October 30, 2024 | marketbeat.comAMI Asset Management Corp Purchases Shares of 51,262 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)AMI Asset Management Corp purchased a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 51,262 shares of the company's stock, valueOctober 30, 2024 | marketbeat.comQ3 2024 Kiniksa Pharmaceuticals Ltd Earnings CallOctober 30, 2024 | uk.finance.yahoo.comKiniksa sees FY24 ARCALYST revenue between $410M-$420MOctober 30, 2024 | markets.businessinsider.comWhat To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 EarningsOctober 29, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio ExecutionOctober 29, 2024 | finanznachrichten.deKiniksa Pharm's Revenue Surges 67% in Q3October 29, 2024 | fool.comKiniksa Pharmaceuticals trading halted, volatility trading pauseOctober 29, 2024 | markets.businessinsider.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Gap Down - Should You Sell?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Gap Down - Here's What HappenedOctober 29, 2024 | marketbeat.comKiniksa Pharmaceuticals International, plc 2024 Q3 - Results - Earnings Call PresentationOctober 29, 2024 | seekingalpha.comKiniksa partners with Carly Pearce in expansion of Life DisRPted campaignOctober 29, 2024 | markets.businessinsider.comKiniksa Pharmaceuticals Q3 2024 Earnings PreviewOctober 29, 2024 | msn.comExploring Kiniksa Pharmaceuticals's Earnings ExpectationsOctober 29, 2024 | benzinga.comHere's What Could Help Kiniksa Pharmaceuticals (KNSA) Maintain Its Recent Price StrengthOctober 29, 2024 | msn.comKiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio ExecutionOctober 29, 2024 | globenewswire.comSemanteon Capital Management LP Buys Shares of 22,057 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Semanteon Capital Management LP purchased a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 22,057 shares of the company's stock, valued at approOctober 29, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 12-Month High - Time to Buy?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 12-Month High - Still a Buy?October 28, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Stock, Option ChainOctober 27, 2024 | benzinga.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Quotes, Forecast and News SummaryOctober 27, 2024 | benzinga.comKiniksa Pharmaceuticals (KNSA) Scheduled to Post Quarterly Earnings on TuesdayKiniksa Pharmaceuticals (NASDAQ:KNSA) will be releasing earnings before the market opens on Tuesday, October 29, Zacks reports.October 23, 2024 | marketbeat.comKiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024October 22, 2024 | globenewswire.comEben Tessari Sells 17,000 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockOctober 18, 2024 | insidertrades.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Sees Significant Drop in Short InterestKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) was the target of a large decrease in short interest in September. As of September 30th, there was short interest totalling 4,090,000 shares, a decrease of 11.9% from the September 15th total of 4,640,000 shares. Based on an average daily trading volume, of 468,500 shares, the short-interest ratio is currently 8.7 days.October 15, 2024 | marketbeat.comBuy Rating on Kiniksa Pharmaceuticals: Expanding Use and Duration of Arcalyst Treatment Signals Revenue GrowthOctober 11, 2024 | markets.businessinsider.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Up 4.1% - Still a Buy?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Up 4.1% - Still a Buy?October 10, 2024 | marketbeat.comBaker Bros. Advisors LP Increases Stake in Kiniksa PharmaceuticalsOctober 9, 2024 | finance.yahoo.comAQR Capital Management LLC Decreases Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)AQR Capital Management LLC lessened its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 20.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 125,995 shares of the company's stockOctober 9, 2024 | marketbeat.comMillennium Management LLC Has $11.61 Million Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Millennium Management LLC raised its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 159.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 621,948 shares of the company's stock after purchasing an additional 382,539 shares duringOctober 8, 2024 | marketbeat.comKiniksa Pharmaceuticals: Looking In On A Developing Growth StoryOctober 7, 2024 | seekingalpha.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Holdings Boosted by Dimensional Fund Advisors LPDimensional Fund Advisors LP boosted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 31.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 664,040 shares of the company's stock after puOctober 7, 2024 | marketbeat.comEben Tessari Sells 17,500 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockSeptember 27, 2024 | insidertrades.comLion Point Capital LP Has $1.96 Million Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Lion Point Capital LP cut its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 19.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 104,691 shares of the company's stock after seSeptember 27, 2024 | marketbeat.comAmgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron InvestorsSeptember 25, 2024 | seekingalpha.comRubric Capital Management LP Acquires 223,094 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Rubric Capital Management LP lifted its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 10.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,419,103 shSeptember 21, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Acadian Asset Management LLCAcadian Asset Management LLC decreased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 65.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,230 shares of the companySeptember 17, 2024 | marketbeat.comKiniksa Pharmaceuticals International, plc (KNSA)September 15, 2024 | finance.yahoo.comBuy Rating Affirmed: Kiniksa Pharmaceuticals’ Arcalyst Poised for Blockbuster Status Amidst Promising Pipeline and Market ExpansionSeptember 14, 2024 | markets.businessinsider.comJefferies Initiates Coverage of Kiniksa Pharmaceuticals (KNSA) with Buy RecommendationSeptember 13, 2024 | msn.com Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. KNSA Media Mentions By Week KNSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNSA News Sentiment▼0.490.46▲Average Medical News Sentiment KNSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNSA Articles This Week▼03▲KNSA Articles Average Week Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ocular Therapeutix News Innoviva News Arcutis Biotherapeutics News Supernus Pharmaceuticals News Pliant Therapeutics News Theravance Biopharma News Blueprint Medicines News Nuvalent News Viking Therapeutics News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNSA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KNSA Stock Alerts